Director, HIV Clinical Trials Program
Section of Infectious Diseases
Yale School of Medicine
New Haven, Connecticut
This activity is intended for physicians, nurse practitioners, physician assistants, and nurses who care for patients with HIV.
Upon completion of this activity, participants should be able to:
- Discuss requirements and antiretroviral therapy (ART) regimen options for treatment initiation and reinitiation
- Identify subsequent regimens for a patient experiencing virologic failure
- Tailor ART regimens to mitigate comorbidities and reduce drug-drug interactions in aging patients with HIV
- Address factors outside of ART regimens that affect a patient’s HIV journey, such as stigma and social determinants of health
HIV is a life-long condition that is becoming increasingly complex. Clinicians must be prepared to face myriad situations over a patient’s lifespan, relating both to their HIV and to either other comorbidities or issues such as stigma or social determinants of health. In this interactive activity, you will follow a patient diagnosed as an adolescent through his lifespan with HIV to make decisions about common challenges. Dr. Onyema Ogbuagu will review rapid ART, educating adolescents, addressing nonadherence due to challenges in social determinants of health, implicit bias, long-acting injectables, virologic failure, switching ART regimens, 2-drug regimens, common comorbidities in aging patients, and drug-drug interactions, all placed in the context of important mile markers along a patient’s HIV journey.
Faculty and Disclosure of Conflicts of Interest
Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Onyema Ogbuagu, MBBCh, FACP, FIDSA: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare; Advisory Board: Janssen Pharmaceuticals, Inc.
The PACE planners and others have no relevant financial relationships to disclose with ineligible companies. The Integritas Communications planners and others have no relevant financial relationships to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Integritas Communications. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 75% on the posttest, and complete the program evaluation.
CME Questions – PACE Contact Information
For information about the accreditation of this program, please contact PACE at https://partnersed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at email@example.com.
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, or Google Chrome
For HTML Client – Google Chrome (v70.0 or above), Mozilla Firefox (v65.0 or above), or Edge (v42.0 or above)
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13, or 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 or above), Apple Safari (v12.0 or above), or Mozilla Firefox (v65.0 or above)